Cargando…
Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer
BACKGROUND: Sarcopenia is prognostic for survival in patients with head and neck cancer (HNC). However, identification of this high-risk feature remains challenging without computed tomography (CT) imaging of the abdomen or thorax. Herein, we establish sarcopenia thresholds at the C3 level and deter...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882831/ https://www.ncbi.nlm.nih.gov/pubmed/35237517 http://dx.doi.org/10.3389/fonc.2022.812159 |
_version_ | 1784659783695990784 |
---|---|
author | Olson, Brennan Edwards, Jared Degnin, Catherine Santucci, Nicole Buncke, Michelle Hu, Jeffrey Chen, Yiyi Fuller, Clifton D. Geltzeiler, Mathew Grossberg, Aaron J. Clayburgh, Daniel |
author_facet | Olson, Brennan Edwards, Jared Degnin, Catherine Santucci, Nicole Buncke, Michelle Hu, Jeffrey Chen, Yiyi Fuller, Clifton D. Geltzeiler, Mathew Grossberg, Aaron J. Clayburgh, Daniel |
author_sort | Olson, Brennan |
collection | PubMed |
description | BACKGROUND: Sarcopenia is prognostic for survival in patients with head and neck cancer (HNC). However, identification of this high-risk feature remains challenging without computed tomography (CT) imaging of the abdomen or thorax. Herein, we establish sarcopenia thresholds at the C3 level and determine if C3 sarcopenia is associated with survival in patients with HNC. METHODS: This retrospective cohort study was conducted in consecutive patients with a squamous cell carcinoma of the head and neck with cross-sectional abdominal or neck imaging within 60 days prior to treatment. Measurement of cross-sectional muscle area at L3 and C3 levels was performed from CT imaging. Primary study outcome was overall survival. RESULTS: Skeletal muscle area at C3 was strongly correlated with the L3 level in both men (n = 188; r = 0.77; p < 0.001) and women (n = 65; r = 0.80; p < 0.001), and C3 sarcopenia thresholds of 14.0 cm(2)/m(2) (men) and 11.1 cm(2)/m(2) (women) were best predictive of L3 sarcopenia thresholds. Applying these C3 thresholds to a cohort of patients with neck imaging alone revealed that C3 sarcopenia was independently associated with reduced overall survival in men (HR = 2.63; 95% CI, 1.79, 3.85) but not women (HR = 1.18, 95% CI, 0.76, 1.85). CONCLUSIONS: This study identifies sarcopenia thresholds at the C3 level that best predict L3 sarcopenia in men and women. In HNC, C3-defined sarcopenia is associated with poor survival outcomes in men, but not women, suggesting sarcopenia may differentially affect men and women with HNC. |
format | Online Article Text |
id | pubmed-8882831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88828312022-03-01 Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer Olson, Brennan Edwards, Jared Degnin, Catherine Santucci, Nicole Buncke, Michelle Hu, Jeffrey Chen, Yiyi Fuller, Clifton D. Geltzeiler, Mathew Grossberg, Aaron J. Clayburgh, Daniel Front Oncol Oncology BACKGROUND: Sarcopenia is prognostic for survival in patients with head and neck cancer (HNC). However, identification of this high-risk feature remains challenging without computed tomography (CT) imaging of the abdomen or thorax. Herein, we establish sarcopenia thresholds at the C3 level and determine if C3 sarcopenia is associated with survival in patients with HNC. METHODS: This retrospective cohort study was conducted in consecutive patients with a squamous cell carcinoma of the head and neck with cross-sectional abdominal or neck imaging within 60 days prior to treatment. Measurement of cross-sectional muscle area at L3 and C3 levels was performed from CT imaging. Primary study outcome was overall survival. RESULTS: Skeletal muscle area at C3 was strongly correlated with the L3 level in both men (n = 188; r = 0.77; p < 0.001) and women (n = 65; r = 0.80; p < 0.001), and C3 sarcopenia thresholds of 14.0 cm(2)/m(2) (men) and 11.1 cm(2)/m(2) (women) were best predictive of L3 sarcopenia thresholds. Applying these C3 thresholds to a cohort of patients with neck imaging alone revealed that C3 sarcopenia was independently associated with reduced overall survival in men (HR = 2.63; 95% CI, 1.79, 3.85) but not women (HR = 1.18, 95% CI, 0.76, 1.85). CONCLUSIONS: This study identifies sarcopenia thresholds at the C3 level that best predict L3 sarcopenia in men and women. In HNC, C3-defined sarcopenia is associated with poor survival outcomes in men, but not women, suggesting sarcopenia may differentially affect men and women with HNC. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8882831/ /pubmed/35237517 http://dx.doi.org/10.3389/fonc.2022.812159 Text en Copyright © 2022 Olson, Edwards, Degnin, Santucci, Buncke, Hu, Chen, Fuller, Geltzeiler, Grossberg and Clayburgh https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Olson, Brennan Edwards, Jared Degnin, Catherine Santucci, Nicole Buncke, Michelle Hu, Jeffrey Chen, Yiyi Fuller, Clifton D. Geltzeiler, Mathew Grossberg, Aaron J. Clayburgh, Daniel Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer |
title | Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer |
title_full | Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer |
title_fullStr | Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer |
title_full_unstemmed | Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer |
title_short | Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer |
title_sort | establishment and validation of pre-therapy cervical vertebrae muscle quantification as a prognostic marker of sarcopenia in patients with head and neck cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882831/ https://www.ncbi.nlm.nih.gov/pubmed/35237517 http://dx.doi.org/10.3389/fonc.2022.812159 |
work_keys_str_mv | AT olsonbrennan establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer AT edwardsjared establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer AT degnincatherine establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer AT santuccinicole establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer AT bunckemichelle establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer AT hujeffrey establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer AT chenyiyi establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer AT fullercliftond establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer AT geltzeilermathew establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer AT grossbergaaronj establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer AT clayburghdaniel establishmentandvalidationofpretherapycervicalvertebraemusclequantificationasaprognosticmarkerofsarcopeniainpatientswithheadandneckcancer |